Inozyme Pharma (INZY) IPO Opens 30% Higher

Today's IPO for Inozyme Pharma, Inc. (NASDAQ: INZY) opened for trading at $20.80 after pricing 7,000,000 shares of common stock at a public offering price of $16 per share.

In addition, Inozyme has granted the underwriters an option for a period of 30 days to purchase up to 1,050,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered and sold by Inozyme.

BofA Securities, Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.

You May Also Be Interested In

• YPF Energía Eléctrica S.A. files for proposed NYSE IPO
• MBX Biosciences names new CEO and CFO amid leadership shift
• Apnimed files for initial public offering on Nasdaq